Brief: Aileron Therapeutics Announces Initiation Of Randomized, Double-Blind, Placebo-Controlled Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer
01/07/2021 13:13
July 1 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS ANNOUNCES INITIATION OF RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ALRN-6924 IN PATIENTS
WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Source text for Eikon: ID:nGNX661B1L
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering